Our Mission

Asgard Therapeutic’s mission is to pioneer direct cell reprogramming for cancer immunotherapy.

Our current focus is to develop scalable reprogramming technologies enabling the direct in vivo conversion of cancer cells into professional antigen-presenting dendritic cells, reinstating cancer immunity.

Our Story

In Greek mythology, the Trojan War was fought between the Greeks and Trojans. After 10 years of conflict, the Greeks implemented a strategy based on a hollow wooden horse, the Trojan horse, to enter Troy and win the war from within. According to Norse myths, while the city of Troy was completely devastated, thousands of Trojans left after the war and moved north across Europe. When they arrived to the Baltic Sea in Scandinavia, they built Asgard, a fortified city resembling Troy and described as “Troy in the north”, the city of Gods.

In 2015, at the University of Coimbra, Portugal, Asgard’s scientific founders started working on a direct cell reprogramming approach to set in motion immune responses based on the unique properties of Dendritic Cells. While reprogramming approaches had been mainly restricted to regenerative medicine, this conceptual shift opens exciting opportunities to merge the fields of cell reprogramming and cancer immunotherapy.

In 2017, the same team of scientists, just like the Trojans, crossed Europe and moved to Lund University in Sweden where they established Asgard Therapeutics AB with support from LU Holding AB to explore and develop the lead program AT-108 based on the Trojan Horse concept (TrojanDC) and its applications in cancer immunotherapy.

€30 M Series A Investment

Asgard Therapeutics raises €30M Series A financing to support development of AT-108 in a round co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

March 2024

Restoring Tumor Immunogenicity with DC Reprogramming in Science Immunology

Publication demonstrating reprogramming of over 60 mouse and human tumor cells across a broad spectrum otumor types into functional antigen-presenting cells. 

July 2023

Women in Tech EU Grant

Asgard Therapeutics has been awarded with a European Innovation Council WomenTechEU grant among 467 companies.

April 2023

Human iDCs in Science Immunology

Publication describing efficient dendritic cell direct reprogramming in human cells and giving mechanistic insight in the cooperative action of the reprogramming factors.

March 2022

Lab at Smile Incubator

Asgard Therapeutics takes the next step as a member of SmiLe Incubator and establishes its own laboratory in Sweden’s largest incubator in life sciences.

November 2021

EUR 6M in Seed Investment

Asgard Therapeutics raises EUR 6M to exploit direct in vivo reprogramming in a Seed round co-led by Novo Holdings, Boehringher Ingelheim Venture Fund and Industrifonden.

October 2021


Asgard Therapeutics’ project awarded EUR 2M by EUREKA Eurostars as a next step after the H2020 SME instrument phase 1.

October 2021

SWElife Innovation Grant

Asgard Therapeutics awarded with Sweden’s SWElife Innovation Grant, a strategic innovation program funded by the Swedish Government.

March 2021

VINNOVA Innovativa Startups

Asgard Therapeutics awarded Innovativa Startups Step 1 and Step 2 from Vinnova, Sweden’s innovation agency.

April 2020

BII Pre-seed Grant

Filipe Pereira’s lab awarded with a Bio Innovation Institute (BII) Pre-Seed grant as a follow-up to the Novo Nordisk Fonden Exploratory Pre-Seed Grant.

March 2020

Asgard Therapeutics AB

Incorporation of Asgard Therapeutics AB with support from LU Holding AB.

December 2018

Induced DCs (iDCs) in Science Immunology

Publication identifying combination of factors able to induce dendritic cell direct reprogramming in mouse cells.

December 2018

Our investors

Novo Holdings A/S

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value.

Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutic-focused biotechnology companies. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs.


Industrifonden is a Nordic venture capital investor based in Stockholm that invests in breakthrough technologies and science-based innovation – the Industry of Tomorrow. Industrifonden areas of expertise include Life Sciences, Deep Tech and Transformative Tech.